FXH - ETF AI Analysis
Top Page
First Trust Health Care AlphaDEX Fund (FXH)
FXH, the First Trust Health Care AlphaDEX Fund, earns a solid overall rating driven mainly by strong, growing healthcare companies like Globus Medical, Medpace, and Dexcom, which show robust financial performance and positive earnings outlooks. However, some holdings such as Centene, with profitability challenges, and names facing legal or cash flow issues slightly weigh on the fund’s quality, and investors should note the key risk that the ETF is concentrated in the healthcare sector, making it sensitive to industry-specific pressures and regulations.
FXH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.16B
- Region
- North America
- Expense Ratio
- 0.61%
- Beta
- 0.62
- Issuer
- First Trust
- Inception Date
- May 08, 2007
- Dividend Yield
- 0.53%
- Asset Class
- Equity
- Index Tracked
- StrataQuant Health Care Index
FXH Summary
FXH is an exchange-traded fund that focuses on the U.S. health care sector, following the StrataQuant Health Care Index. It holds a mix of companies involved in pharmaceuticals, biotech, medical equipment, and health care services. Well-known names in the fund include Cigna and Centene. Investors might consider FXH if they want growth potential from medical innovation and a way to diversify into health care without picking individual stocks. A key risk is that the fund is heavily concentrated in health care, so its value can rise or fall sharply if the sector faces challenges or market downturns.
How much will it cost me?
FXH has an expense ratio of 0.61%, which means you’ll pay about $6.10 per year for every $1,000 invested. This cost is higher than the average ETF because FXH is actively managed using the AlphaDEX strategy rather than simply tracking a broad market index.
What would affect this ETF?
FXH focuses on U.S. health care companies like Centene, Cigna, and medical equipment and services providers, so it could benefit from aging populations, ongoing demand for medical care, and new drug or technology breakthroughs. On the negative side, changes in government health care policies, tighter regulations on drug pricing or insurance, and economic slowdowns that pressure hospital and insurer profits could weigh on the fund, while higher interest rates may also hurt investor appetite for stocks in this sector.
FXH Top 10 Holdings
FXH is leaning hard into U.S. health care, with a bench dominated by fast-moving innovators. Halozyme and Natera have been rising steadily, giving the fund much of its recent spark, while Guardant Health adds more momentum from the precision oncology corner. Medpace has also been climbing, though its rich valuation could cool the pace. On the flip side, Globus Medical looks mixed and Universal Health is dragging, tempering some of the gains. Overall, this is a concentrated bet on U.S. health care growth stories rather than defensive blue chips.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 HALO | Halozyme | 2.63% | $30.68M | $14.86B | 97.81% | 73Outperform |
 CAI | Caris Life Sciences, Inc. | 2.36% | $27.52M | $9.70B | 6.72% | 49Neutral |
 CNC | Centene | 2.42% | $28.13M | $33.89B | 88.10% | 58Neutral |
 CI | Cigna | 2.45% | $28.52M | $78.80B | 20.78% | 72Outperform |
 ZBH | Zimmer Biomet Holdings | 2.47% | $28.78M | $18.03B | -3.19% | 73Outperform |
 MEDP | Medpace Holdings | 2.34% | $27.27M | $18.24B | 10.81% | 79Outperform |
 GMED | Globus Medical | 2.39% | $27.86M | $10.48B | 31.58% | 82Outperform |
 UHS | Universal Health | 2.34% | $27.23M | $10.37B | -16.75% | 74Outperform |
 GH | Guardant Health | 2.16% | $25.14M | $23.99B | 83.54% | 61Neutral |
 NTRA | Natera | 2.07% | $24.08M | $59.72B | 90.48% | 73Outperform |
FXH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FXH, the sentiment is Positive. The current price of 137.67 is above the 20-day moving average (MA) of 133.47, above the 50-day MA of 132.38, and above the 200-day MA of 120.61, indicating a bullish trend. The MACD of 1.73 indicates Negative momentum. The RSI at 64.51 is Neutral, neither overbought nor oversold. The STOCH value of 77.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FXH.
FXH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FXH | $137.67 | $144.00(4.60% Upside) | $1.16B | 0.61% | 71Outperform |
 IYH | $77.60 | $84.20(8.50% Upside) | $4.71B | 0.37% | 73Outperform |
 FHLC | $88.24 | $98.15(11.23% Upside) | $3.95B | 0.08% | 71Outperform |
 IHI | $56.51 | $62.74(11.02% Upside) | $3.62B | 0.37% | 74Outperform |
 FBT | $273.89 | $336.78(22.96% Upside) | $3.13B | 0.55% | 71Outperform |
 IHE | $106.92 | $126.72(18.52% Upside) | $1.62B | 0.37% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FXH | First Trust Health Care AlphaDEX Fund | 137.67 | 27.08 | 24.49% | |
| IYH | iShares U.S. Healthcare ETF | 77.60 | 17.33 | 28.75% | |
| FHLC | Fidelity MSCI Health Care Index ETF | 88.24 | 19.38 | 28.14% | |
| IHI | iShares U.S. Medical Devices ETF | 56.51 | -4.22 | -6.95% | |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 273.89 | 83.79 | 44.08% | |
| IHE | iShares U.S. Pharmaceuticals ETF | 106.92 | 32.14 | 42.97% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.